Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Dog epilepsy research is 'below par'
chocolate labrador
Epilepsy is the most common chronic neurological condition found in both dogs and people.
RVC carries out the first ever systematic review of AED efficacy

Research on the efficacy of canine epilepsy drugs is well below the expected standard, according to a new study by the Royal Veterinary College (RVC).

The first ever systematic review of canine anti-epilepsy drugs (AEDs) revealed that much of the evidence for medical treatment of the condition was based on "subpar testing".

Researchers from the RVC's canine epilepsy clinic reviewed all data published in peer-reviewed journals and publications, and assessed its reliability. According to their findings, only a few of the studies were relatively unbiased and objective.

To evaluate the reliability of the data, RVC researchers explored the evidence quality, study design, study group size, subject enrolment quality and bias risk.

Dr Dave Brodbelt, senior lecturer in companion animal epidemiology, said: "This systematic review revealed that, in veterinary medicine, the quality of evidence provided by the studies for AEDs' efficacy is not yet at a recommended standard.

"Many studies revealed a potential efficacy of a drug, but then there was a lack of follow-up studies of higher quality confirming the initial positive results."

Epilepsy affects 50,000 dogs and 600,000 people in the UK, making it the most common chronic neurological condition found in both dogs and people.

Professor Holger Volk, clinical director of the RVC Small Animal Referral Hospital, said: "Canine epilepsy is a complex condition and can be very distressing for the dog and their owners, therefore it is immensely important the drug treatments we give to our pets have been properly tested in reliable studies."

In light of the findings, RVC researchers recommend veterinary scientists work together more closely to improve the quality of testing. It is also suggested that scientists forge closer relationships with major stakeholders and funders to reduce the risk of bias.

Veterinary medicine should also take its lead from human epilepsy research, using examples such as the International League Against Epilepsy, which works to advance and distribute knowledge about epilepsy, promote research and education and improve the care available to patients.

To view the RVC's systematic review, published in BMC Veterinary Research Journal, visit:
http://www.biomedcentral.com/1746-6148/10/257/abstract

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.